Openings may be found in consolidated genetic/epigenetic sequencing workflows, linksbetween chromatin changes and disease states, and reversible epigenetic changes.
The Pancreatic Cancer Action Network logo
CLEVELAND, Ohio, June 9, 2021 /PRNewswire/ GenomOncology announced today that the Pancreatic Cancer Action Network (PanCAN) has chosen to upgrade to GenomOncology s Precision Decision to further enhance the free clinical trial matching services it offers to pancreatic cancer patients.
Through its comprehensive Patient Services program, PanCAN is committed to matching patients to the best treatment opportunities to create a world in which all patients with pancreatic cancer will thrive. PanCAN strongly recommends pancreatic cancer patients consider clinical trials at diagnosis as well as during every treatment decision, and according to research from the organization, patients who receive treatment based on their tumor s biological characteristics have better outcomes.